Get 15% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the transmucosal drug delivery devices market grown over the years?
The market for transmucosal drug delivery devices has experienced significant growth in the past few years. The market value is set to rise from $50.24 billion in 2024 to $55.04 billion in 2025 with a compound annual growth rate (CAGR) of 9.6%. This growth during the historic period is due to several factors including the demand for quick relief from angina, the efficiency of sublingual delivery for immediate absorption into the blood, the aim to avoid gastrointestinal degradation, the creation of buccal tablets, and the requirement for non-invasive administration of peptides and proteins.
What Is the forecasted market size and growth rate for the transmucosal drug delivery devices market?
In the upcoming years, the transmucosal drug delivery devices market is predicted to experience robust growth, with a rise to $78.21 billion by 2029 at a compound annual growth rate (CAGR) of 9.2%. The expected expansion during the prediction period can be linked to the creation of sophisticated drug delivery systems, the climbing incidence of chronic diseases, an increased emphasis on tailored therapy, an aging demographic with greater demand for medication, and heightened awareness. Notable trends during the forecast period encompass extensions in therapeutic applications, personalization of drug delivery devices to suit individual medicine, regulatory accreditations and guidelines, emerging markets, environmentally friendly devices, and inventive formulations.
Get your transmucosal drug delivery devices market report here!
What are the major factors driving growth in the transmucosal drug delivery devices market?
The escalating occurrence of long-term medical conditions is anticipated to stimulate the transmucosal drug delivery devices market’s expansion in the future. Chronic illnesses are typically slow-progressing, long-standing health issues that often require continuous medical intervention to manage symptoms and prevent complications from escalating. The increase in chronic diseases can be attributed to lifestyle choices, aging demographics, environmental influences, challenges within the healthcare infrastructure, and urbanization. Transmucosal drug delivery devices are commonly utilized in chronic disease management ensuring efficient and controlled medication delivery that maintains therapeutic levels to manage symptoms and enhance patient compliance. For example, the Leukemia & Lymphoma Society (LLS), a philanthropic organization based in the US, reported in August 2023 that someone is diagnosed with leukemia, lymphoma, or myeloma every three minutes in the US. It estimated that out of the projected 1,958,310 new cancer cases in 2023, 184,720 diagnoses, or 9.4%, would be of these diseases. Therefore, the surging cases of chronic diseases are fueling the growth of the transmucosal drug delivery devices market.
What key areas define the segmentation of the global transmucosal drug delivery devices Market?
The transmucosal drug delivery devices market covered in this report is segmented –
1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery
2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types
3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications
4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals
Subsegments:
1) By Passive Transdermal Drug Delivery: Reservoir Systems, Matrix Systems, Micro-Needle Systems, Pressure-Sensitive Adhesive Systems
2) By Active Transdermal Drug Delivery: Iontophoresis, Sonophoresis, Electroporation, Thermal Ablation, Microporation
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp
Who are the key players steering the development of the transmucosal drug delivery devices market?
Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd.
How are evolving market trends shaping transmucosal drug delivery devices Strategies?
Leading firms involved in the production of transmucosal drug delivery devices are focusing on the development of innovative smart platforms such as unique transdermal patch delivery systems to augment drug absorption and better patient adherence and convenience. These unique transdermal patch delivery methods refer to particular technologies owned by firms that allow the administration of drugs via the skin, guaranteeing controlled release and improved therapeutic results. For example, in January 2024, Starton Therapeutics Inc, a biotechnology company based in the US, introduced STARSILON, a new unique transdermal patch delivery system, intended for prolonged use to facilitate the therapeutic delivery of APIs which are difficult to formulate. This broadens the possibilities for transdermal drug delivery for challenging active pharmaceutical ingredients (APIs) by boosting therapeutic effectiveness with stable delivery rates.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16812
What regions are contributing significantly to the growth of the transmucosal drug delivery devices market?
North America was the largest region in the transmucosal drug delivery devices market in 2024. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Implantable Drug Delivery Devices Global Market Report 2024
Injectable Drug Delivery Devices Global Market Report 2024
Drug Delivery Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
